Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: The LIPID study

International Journal of Cardiology

Volumn 172, Issue 2, 2014, Pages 411-418

  Funke Kaiser, Anne ^a   Mann, Kristy ^b   Colquhoun, David ^c   Zeller, Tanja ^a   Hunt, David ^d   Simes, John ^b   Sullivan, David ^b   Sydow, Karsten ^a   West, Malcolm ^e   White, Harvey ^f   Blankenberg, Stefan ^a   Tonkin, Andrew M ^d  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESLEY HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f Green Lane Cardiovascular Service ^*  (New Zealand)

Author keywords

Biomarker; Coronary heart disease; Heart failure; LIPID study; Midregional proadrenomedullin; Risk factors

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MIDREGIONAL PROADRENOMEDULLIN; PLACEBO; PRAVASTATIN; PROADRENOMEDULLIN; UNCLASSIFIED DRUG; ADRENOMEDULLIN; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN PRECURSOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; DISCRIMINANT ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NET RECLASSIFICATION IMPROVEMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; BLOOD; CONTROLLED STUDY; CORONARY DISEASE; FOLLOW UP; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT;

ADRENOMEDULLIN; ADULT; AGED; BIOLOGICAL MARKERS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PRAVASTATIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; RECURRENCE; RISK ASSESSMENT;

EID: 84900622436     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.01.064     Document Type: Article

References (29)

1. Global status report on noncommunicable diseases 2010 / [World Health Organization] 2011 World Health Organization Geneva, Switzerland [Chapter 1. http://www.who.int/nmh/publications/ncd-report-chapter1.pdf (11 July 2013)]
2. R.B. Schnabel, A. Schulz, and C.M. Messow et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease Eur Heart J 31 24 2010 3024 3031
3. L.G. Gilstrap, and T.J. Wang Biomarkers and cardiovascular risk assessment for primary prevention: an update Clin Chem 58 1 2012 72 82
4. K. Thygesen, J. Mair, and C. Mueller et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care Eur Heart J 33 2012 2001 2006
5. R. Schnabel, E. Lubos, and H.J. Rupprecht et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study J Am Coll Cardiol 47 3 2006 552 558
6. J. Struck, C. Tao, N.G. Morgenthaler, and A. Bergmann Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients Peptides 25 8 2004 1369 1372
7. K. Kitamura, K. Kangawa, and M. Kawamoto et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma Biochem Biophys Res Commun 192 2 1993 553 560
8. K. Kitamura, K. Kangawa, and T. Eto Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions Microsc Res Tech 57 1 2002 3 13
9. K. Kobayashi, K. Kitamura, and N. Hirayama et al. Increased plasma adrenomedullin in acute myocardial infarction Am Heart J 131 4 1996 676 680
10. K. Kobayashi, K. Kitamura, and T. Etoh et al. Increased plasma adrenomedullin levels in chronic congestive heart failure Am Heart J 131 5 1996 994 998
11. M. Potocki, T. Breidthardt, and T. Reichlin et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure J Intern Med 267 1 2010 119 129
12. S. Masson, R. Latini, and E. Carbonieri et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial Eur J Heart Fail 12 4 2010 338 347
13. A. Gegenhuber, J. Struck, and B. Dieplinger et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure J Card Fail 13 1 2007 42 49
14. A. Maisel, C. Mueller, and R. Nowak et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial J Am Coll Cardiol 55 19 2010 2062 2076
15. S.Q. Khan, R.J. O'Brien, and J. Struck et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study J Am Coll Cardiol 49 14 2007 1525 1532
16. P.S. Wild, R.B. Schnabel, and E. Lubos et al. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study Clin Chem 58 1 2012 226 236
17. The LIPID Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
18. I.C. Marschner, D. Colquhoun, and R.J. Simes et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators J Am Coll Cardiol 38 1 2001 56 63
19. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 4 1996 361 387
20. S.S. Bhandari, J.E. Davies, J. Struck, and L.L. Ng Influence of confounding factors on plasma mid-regional pro-adrenomedullin and mid-regional pro-A-type natriuretic peptide concentrations in healthy individuals Biomarkers 16 3 2011 281 287
21. Y. Li, C. Jiang, X. Wang, Y. Zhang, S. Shibahara, and K. Takahashi Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues Peptides 28 5 2007 1129 1143
22. M.S. Sabatine, D.A. Morrow, and J.A. de Lemos et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease Circulation 125 2 2012 233 240
23. A.M. Richards, M.G. Nicholls, and T.G. Yandle et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction Circulation 97 19 1998 1921 1929
24. T. Katayama, H. Nakashima, S. Furudono, Y. Honda, S. Suzuki, and K. Yano Evaluation of neurohumoral activation (adrenomedullin, BNP, catecholamines, etc.) in patients with acute myocardial infarction Intern Med 43 11 2004 1015 1022
25. O.S. Dhillon, S.Q. Khan, and H.K. Narayan et al. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study J Am Coll Cardiol 56 2 2010 125 133
26. P. Niu, T. Shindo, and H. Iwata et al. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage Circulation 109 14 2004 1789 1794
27. H. Romppanen, M. Marttila, and J. Magga et al. Adrenomedullin gene expression in the rat heart is stimulated by acute pressure overload: blunted effect in experimental hypertension Endocrinology 138 6 1997 2636 2639
28. T. Tsuruda, J. Kato, and K. Kitamura et al. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes Hypertension 31 1 Pt 2 1998 505 510
29. S. Blankenberg, M.J. McQueen, and M. Smieja et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study Circulation 114 3 2006 201 208